Frequency of MOG-IgG in cerebrospinal fluid versus serum.
作者信息
Pace Samuel, Orrell Michael, Woodhall Mark, Palace Jacqueline, Leite Maria Isabel, Irani Sarosh R, Waters Patrick, Handel Adam E
机构信息
Medical School, University of Oxford, Oxford, Oxfordshire, UK.
Oxford Autoimmune Neurology Group, University of Oxford, Oxford, Oxfordshire, UK.
出版信息
J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):334-335. doi: 10.1136/jnnp-2021-326779. Epub 2021 Jul 14.
Abstract
摘要
相似文献
1
Frequency of MOG-IgG in cerebrospinal fluid versus serum.
J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):334-335. doi: 10.1136/jnnp-2021-326779. Epub 2021 Jul 14.
2
Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
Mult Scler Relat Disord. 2024 May;85:105526. doi: 10.1016/j.msard.2024.105526. Epub 2024 Mar 9.
3
Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
JAMA Neurol. 2019 Mar 1;76(3):301-309. doi: 10.1001/jamaneurol.2018.4053.
4
Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
JAMA Ophthalmol. 2018 Apr 1;136(4):419-422. doi: 10.1001/jamaophthalmol.2017.6757.
5
The clinical relevance of MOG antibody testing in cerebrospinal fluid.
Ann Clin Transl Neurol. 2024 Sep;11(9):2514-2519. doi: 10.1002/acn3.52163. Epub 2024 Jul 28.
6
MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment.
J Neurol. 2024 May;271(5):2840-2843. doi: 10.1007/s00415-024-12180-z. Epub 2024 Jan 27.
7
Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
J Neurol. 2024 May;271(5):2662-2671. doi: 10.1007/s00415-024-12213-7. Epub 2024 Feb 16.
8
Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
Eur J Neurol. 2016 Mar;23(3):580-7. doi: 10.1111/ene.12898. Epub 2015 Nov 22.
9
Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system.
J Neuroimmunol. 2014 May 15;270(1-2):98-9. doi: 10.1016/j.jneuroim.2014.03.001. Epub 2014 Mar 11.
10
Myelin Oligodendrocyte Glycoprotein Antibody Associated Transverse Myelitis.
Acta Medica (Hradec Kralove). 2019;62(3):123-126. doi: 10.14712/18059694.2019.136.
引用本文的文献
1
Biomarkers for diagnosis and prognosis of myelin oligodendrocyte glycoprotein antibody-associated disease - review article.
Front Immunol. 2025 Jun 6;16:1594960. doi: 10.3389/fimmu.2025.1594960. eCollection 2025.
2
The clinical relevance of MOG antibody testing in cerebrospinal fluid.
Ann Clin Transl Neurol. 2024 Sep;11(9):2514-2519. doi: 10.1002/acn3.52163. Epub 2024 Jul 28.
3
MOG Antibody Disease: Nuances in Presentation, Diagnosis, and Management.
Curr Neurol Neurosci Rep. 2024 Aug;24(8):219-232. doi: 10.1007/s11910-024-01344-z. Epub 2024 May 28.
4
MOG antibody-associated optic neuritis.
Eye (Lond). 2024 Aug;38(12):2289-2301. doi: 10.1038/s41433-024-03108-y. Epub 2024 May 23.
5
Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid.
Ann Neurol. 2024 Jul;96(1):34-45. doi: 10.1002/ana.26931. Epub 2024 Apr 9.
6
Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
J Neurol. 2024 May;271(5):2662-2671. doi: 10.1007/s00415-024-12213-7. Epub 2024 Feb 16.
7
[Diagnostic value of low versus high titers of MOG-IgG and their clinical implications in myelin oligodendrocyte glycoprotein antibody-associated disease: a retrospective singlecenter study].
Nan Fang Yi Ke Da Xue Xue Bao. 2023 Nov 20;43(11):1865-1873. doi: 10.12122/j.issn.1673-4254.2023.11.05.
8
Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders.
Neurol Clin. 2024 Feb;42(1):77-114. doi: 10.1016/j.ncl.2023.06.009. Epub 2023 Aug 7.
9
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria.
Neurol Neuroimmunol Neuroinflamm. 2023 Nov 17;11(1). doi: 10.1212/NXI.0000000000200183. Print 2024 Jan.
10
Basic CSF parameters and MRZ reaction help in differentiating MOG antibody-associated autoimmune disease versus multiple sclerosis.
Front Immunol. 2023 Sep 6;14:1237149. doi: 10.3389/fimmu.2023.1237149. eCollection 2023.
本文引用的文献
1
Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
Neurology. 2021 Jul 6;97(1):e1-e12. doi: 10.1212/WNL.0000000000012175. Epub 2021 May 12.
2
Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
Neurology. 2019 Nov 12;93(20):e1867-e1872. doi: 10.1212/WNL.0000000000008479. Epub 2019 Oct 23.
3
A multicenter comparison of MOG-IgG cell-based assays.
Neurology. 2019 Mar 12;92(11):e1250-e1255. doi: 10.1212/WNL.0000000000007096. Epub 2019 Feb 6.
4
Clinical significance of assaying anti-MOG antibody in cerebrospinal fluid in MOG-antibody-associated diseases: A case report.
Mult Scler Relat Disord. 2019 Feb;28:165-166. doi: 10.1016/j.msard.2018.12.035. Epub 2018 Dec 29.
5
Clinical presentation and prognosis in MOG-antibody disease: a UK study.
Brain. 2017 Dec 1;140(12):3128-3138. doi: 10.1093/brain/awx276.
6
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
J Neuroinflammation. 2016 Sep 26;13(1):279. doi: 10.1186/s12974-016-0717-1.
Zotero 插件